干眼症人工泪液固定与按需使用的临床结局:6周观察者掩蔽4期试验
这项前瞻性、多中心、观察者掩蔽、活性对照、平行组试验将干眼症患者按1:2随机分配至PEG/PG人工泪液每日四次(QID)组(n=34)或按需(PRN)组(n=63)使用28天。第28天,QID组与PRN组的总眼表染色评分(TOSS)最小二乘均值变化分别为-1.19和-0.94,未证实QID优于PRN;IDEEL症状困扰评分变化分别为-7.0和-2.94,QID组更优(P=0.037)。
要点
- 第28天TOSS评分QID组变化-1.19 vs PRN组-0.94,未证实QID优效。
- IDEEL症状困扰评分QID组-7.0 vs PRN组-2.94,QID组更优(P=0.037)。
- 两组不良事件发生率均≤3.2%,未报告严重不良事件。
核心结论
- 就眼表染色而言,PEG/PG每日四次(QID)使用未优于按需(PRN)使用。
- IDEEL症状困扰评分有利于QID使用,提示规律使用人工泪液可能比PRN使用提供更好的症状缓解。
研究设计与样本
- 前瞻性、多中心、观察者掩蔽、活性对照、平行组试验。
- 参与者按1:2随机分配至PEG/PG每日四次(QID)组(n=34)或按需(PRN)组(n=63),使用28天。
- 主要终点为第28天总眼表染色(TOSS)评分(Oxford量表)较基线的变化。
主要发现
- 第28天,QID组和PRN组TOSS评分最小二乘均值较基线变化分别为-1.19和-0.94,治疗差异(TD)为-0.26(95%CI:-∞至0.21;P=0.184)。
- 未证实QID优于PRN,因TD单侧95%CI上限未小于0(预设界值)。
- 第28天,QID组和PRN组IDEEL症状困扰评分最小二乘均值较基线变化分别为-7.0和-2.94(TD:-4.06,P=0.037)。
- 第28天,QID组和PRN组IDEEL治疗有效性评分变化分别为2.43和0.16(TD:2.28,P=0.278)。
- 第28天,QID组和PRN组IDEEL治疗相关不便评分变化分别为-11.56和-2.77(TD:-8.8,P=0.996)。
关键数值与推荐
- 主要终点TOSS评分第28天QID组变化-1.19 vs PRN组-0.94,TD -0.26(95%CI:-∞至0.21;P=0.184)。
- IDEEL症状困扰评分QID组变化-7.0 vs PRN组-2.94(TD:-4.06,P=0.037)。
- IDEEL治疗有效性评分QID组变化2.43 vs PRN组0.16(TD:2.28,P=0.278)。
- IDEEL治疗相关不便评分QID组变化-11.56 vs PRN组-2.77(TD:-8.8,P=0.996)。
- 两组不良事件发生率均≤3.2%,未报告严重不良事件。
临床怎么用
- 对于干眼症患者,规律每日四次使用PEG/PG人工泪液在眼表染色改善方面未显示优于按需使用。
- 规律每日四次使用在IDEEL症状困扰评分上优于按需使用,可能提供更好的症状缓解。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the clinical effects of using fixed (four times daily [QID]) versus as-needed (PRN) dosing of an artificial tear product (polyethylene glycol/propylene glycol [PEG/PG]; Systane Ultra) in individuals with dry eye disease. METHODS: In this prospective, multicenter, observer-masked, active-control, parallel-group trial, participants were randomized (1:2 allocation) to receive 1 drop of PEG/PG QID (n = 34) or PRN (n = 63) for 28 days. The primary endpoint was change from baseline in the total ocular surface staining (TOSS) score (according to the Oxford scale) at day 28. RESULTS: At day 28, the change from baseline in least squares mean (LSM) TOSS scores for QID and PRN groups were -1.19 and -0.94, respectively (treatment difference [TD]: -0.26; 95% confidence interval [CI]: -∞ to 0.21; P = 0.184); superiority of QID versus PRN dosing was not established, as the upper limit of one-sided 95% CI for TD was not <0 (prespecified limit). At day 28, for QID and PRN groups, the LSM change from baseline in Impact of Dry Eye on Everyday Life (IDEEL) scores was symptom-bother, -7.0 and -2.94 (TD: -4.06, P = 0.037); treatment effectiveness, 2.43 and 0.16 (TD: 2.28, P = 0.278); and treatment-related inconvenience, -11.56 and -2.77 (TD: -8.8, P = 0.996), respectively. Incidence of adverse events was low (≤3.2%) in both the groups; no serious adverse events were reported. CONCLUSIONS: QID dosing of PEG/PG was not superior to PRN dosing in terms of ocular staining. The IDEEL symptom-bother score favored QID dosing, suggesting that regular use of artificial tears may provide better symptomatic relief than PRN use. (ClinicalTrials.gov number, NCT02446015.).
引用
- Asbell P, Vingrys AJ, Tan J, et al. Clinical Outcomes of Fixed Versus As-Needed Use of Artificial Tears in Dry Eye Disease: A 6-Week, Observer-Masked Phase 4 Clinical Trial. Invest Ophthalmol Vis Sci. 2018. PMID: 29715369. doi:10.1167/iovs.17-23733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。